Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $8.22 EPS, Q3 2025 earnings at $9.62 EPS, Q4 2025 earnings at $9.56 EPS, FY2025 earnings at $34.47 EPS ...

A comprehensive examination of how financial experts perceive Regeneron Pharmaceuticals is ... Neutral | $759.00|$940.00 | |David Risinger |Leerink Partners |Raises |Outperform | $834.00|$762. ...

Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $762.00 to $834. ...

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.

Leerink initiated coverage of Spyre Therapeutics (SYRE) with an Outperform rating and $45 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Regeneron stock tumbled Tuesday after the biotech giant reported a major revenue miss due to light sales of its eye drug Eylea.